Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim data from Part 1 of an ongoing phase 1/2 trial of ARO-C3 in healthy people as a potential therapy for complement mediated diseases. The ...
ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
Wieme, R. J., Demeulenaere, L., and Segers, J., Prot. Biol. Fluids (Proc. Fifteenth Colloq., Bruges), 15, 499 (Elsevier, Amsterdam, 1968).
The complement system is part of the body's immune system to fight pathogens and remove cell debris; its role in two autoimmune diseases and a mental disorder is a surprise Variants in a gene of the ...
When told what to kill, the complement system deftly deals the final blows—helping the immune system purge away pathogens and infected cells. But in the nervous system, debate rages as to whether this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results